article thumbnail

Skinny-Label Lives to See Another Day

The FDA Law Blog

Koblitz — Further talks of the Skinny Label’s demise may be premature, as demonstrated by a new decision from the District Court for the District of Columbia upholding FDA’s interpretation of the “same labeling” provisions of the Hatch-Waxman Amendments. Teva and Amarin v. Citing to “[b]inding Circuit law” in Bristol-Myers Squibb v.

article thumbnail

Gluten in Medications: Why Labeling Matters for Patients With Celiac Disease

Drug Topics

Despite pleas from celiac disease advocates, the FDA still does not require drug manufacturers to note on the label whether a medication contains gluten.

Labelling 201
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Lawmakers want FTC to probe big PBMs over private-label biosimilar deals

STAT

In reality, the arrangements actually resemble private-label distribution, but the lawmakers worry these agreements could cause consumers to pay higher prices. These new business units have since used these deals as springboards to market the medications to health plans.

Labelling 125
article thumbnail

Reducing Medication Errors Through Product Label Changes

PharmExec

Laura Johnson, senior director, sales, life sciences, Loftware, discusses innovations in label design that could lead to improved patient outcomes and less medical errors.

article thumbnail

Can Patient-Centered Prescription Labels Increase Medication Adherence?

Drug Topics

Researchers evaluated how changes in USP labeling standards have affected adherence across multiple classes of drugs.

Labelling 186
article thumbnail

Ensuring That Product Labels Are Easily Understood

PharmExec

Laura Johnson, senior director, sales, life sciences, Loftware, discusses ways to ensure that product labels are easily understood universally.

article thumbnail

STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label

STAT

regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment. Novo said it has also filed for a label expansion in Europe and a decision is expected this year.

Labelling 143